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Availability of extended-release naltrexone may increase the number of opioid- 
dependent individuals in treatment. Extension of a randomized clinical trial  
 
Abstract 
Background and objective: Opioid maintenance treatment (OMT) is highly available in 
Norway, but only 50% of opioid-dependent individuals are enrolled in such programs. We 
aimed to examine if availability of extended-release naltrexone (XR-NTX) could attract 
individuals who for different reasons were not enrolled in an OMT program. Methods: In a 
Norwegian clinical study, n=117 opioid-dependent adults volunteered to receive XR-NTX in a 
9-month period, as an extension of a previous randomized clinical trial. Results: Before 
study inclusion, 40.2% (n=47) of the study participants were not enrolled in OMT while the 
remainder were recruited from OMT. Participants not enrolled in OMT displayed more 
ongoing severe addiction-related problems such as heroin use (p=0.002) but displayed a 
higher retention in treatment in the 9-month extension study (p=0.048 for log-rank test) than 
participants enrolled in OMT. Conclusion: Availability of XR-NTX attracted opioid-dependent 
individuals not previously enrolled in available OMT. While OMT may be perceived as a 
burden with regard to daily intake and control measures, one-monthly injections with XR-NTX 
may be perceived favourable offering more freedom to the patients, is being not addictive 
and reduces heroin craving. We suggest that an introduction of XR-NTX in Europe may 
increase the number of opioid-dependent individuals in treatment.   
 
Introduction 
It is of great importance to increase the overall number of opioid-dependent individuals in 
treatment, since treatment is the most crucial factor to prevent overdoses and reduce 
negative consequences of illicit opioid use for society (1, 2). The current recommended 
treatment option for opioid dependence is maintaining physical opioid dependence with 
opioid agonists like methadone or buprenorphine through opioid maintenance treatment 
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programs (OMT) (3). OMT has shown well-documented improvements in illicit drug use, 
criminal behaviour and reduced risk of overdoses deaths (1, 4-9). A Norwegian study found 
that only 5-10% of the overdose deaths among opioid-dependent individuals occurred in 
patients enrolled in an OMT program, emphasizing  the importance of such treatment 
programs (10). As for the majority of European countries, OMT in Norway is managed 
according to a low-threshold treatment guideline. However, despite its personal and societal 
advantages and the relatively free access to OMT in many European countries, it is 
estimated that only around 50% of opioid-dependent individuals in Europe receive such 
treatment (11).  
Extended-release naltrexone (XR-NTX) is an alternative pharmacological treatment option 
for opioid dependence (2, 12). Naltrexone is an opioid antagonist that competitively blocks 
the effects of exogenous opioids (e.g., heroin) upon relapse and pharmacologically reduces 
cravings for opioids and alcohol (13-18). Naltrexone is considered as being a safe drug with 
few severe side-effects (13, 19-23). It lacks any potential for addiction and abuse (4), and 
prevents overdoses when used as described (24, 25). XR-NTX is administered as an 
intramuscular depot injection every fourth week, which may be perceived as favourable, 
compared to daily prescribed agonist treatment (26, 27). Two recently published randomized 
controlled trials (RCT) suggest that XR-NTX is as effective as buprenorphine-naloxone (BP-
NLX) in retaining users in treatment and in reducing opioid use (28, 29). Both studies 
however, experienced dropouts from participants who failed to complete the mandatory 
detoxification period before naltrexone induction (28, 29). 
XR-NTX is so far only approved in Russia and in the US, and most previous research has 
been conducted in these countries (12, 30). Since OMT is illegal in Russia but highly 
accessible in most Western European countries, the setting for the utilisation of XR-NTX is 
not comparable between Russia and Western Europe. Despite its demonstrated clinical 
effectiveness and broad insurance coverage, XR-NTX use in the United States has been 
limited, in part due to billing complexity and cost concerns (31). 
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Two European user surveys have suggested that opioid-dependent individuals would 
welcome abstinence support with XR-NTX as a treatment option (32, 33), but such surveys 
are methodological limited to measuring attitudes rather than behaviour. Until recently, it has 
not been known how XR-NTX will be utilized in a clinical setting where OMT is easily 
available at no cost for the individual. Results from a Norwegian treatment study however, 
indicate that XR-NTX could be an alternative treatment option to a number of opioid-
dependent individuals in Europe (28, 34).  
As in many other European countries, substance use disorder (SUD) treatment programs in 
Norway are a part of the national health care system and available at no cost to users. Very 
few patients are rejected when applying for the program. In 2015, n=7498 patients received 
treatment in OMT, estimated to be at least 50% of the Norwegian population of opioid-
dependent individuals (35). 
The overall objective of this study was to examine if XR-NTX could have the potential to 
increase the number of opioid-dependent individuals in treatment. We conducted a 
secondary analysis of a previous reported follow-up study (34), and aimed to identify 
possible differences in baseline characteristics and retention rates among participants, based 
on their affiliation to OMT before study inclusion.  
Methods  
In the aforementioned follow-up study, n=117 participants volunteered for treatment with XR-
NTX for a 9-month period (34). This was a subsequent follow-up to a previous published 
RCT (28).  
Design and setting 
The study was organized by The Norwegian Centre of Addiction Research (SERAF) and 
conducted in a naturalistic clinical setting at five urban hospitals in Norway from November 
2012 to July 2015 (36). To be eligible, the opioid-dependent individuals must be willing to 
register in the national OMT program via one of the study hospitals after inclusion in the 
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study but before study medication was administered. This guaranteed the participants’ 
access to buprenorphine or methadone at no cost should they need so in the event of 
discontinuation from the study. Information about the study was given to opioid-dependent 
individuals at OMT clinics, detoxification units and other services. In a naturalistic manner, 
peer-based recommendations were permitted. At the time of this study XR-NTX was not 
registered for clinical use in Europe or Norway. XR-NTX was available only through the 
study, which was assumed to be the participants’ primary motivation for volunteering for 
participation.     
Participants 
The participants in the 9-month follow-up study were recruited among those who were 
randomized in the RCT (28). In addition to the RCT completers, those who dropped-out 
during the RCT were offered re-inclusion in the 9-month follow-up (34). Participants were 
adults between 18 and 60 years old with opioid dependence disorder (DSM-IV). Before 
inclusion, all eligible patients underwent a general medical examination. Patients with serious 
somatic diseases, such as acute hepatic failure or an AIDS indicator disease were excluded 
from the study. Likewise, patients with serious chronic or acute mental disorders, such as 
psychosis or suicidality, were also non-eligible. Patients with less severe somatic or mental 
disorders were eligible for participation. Pregnant or breast-feeding women were excluded 
from participation, and female participants had to consent to use contraception during their 
participation in the study (36).  
Screening procedures 
Before inclusion in the RCT, all eligible patients were screened for serious mental disorders 
using the MINI 6.0 interview (37). They underwent interviews using the European version of 
the Addiction Severity Index (Europ-ASI) and completed several self-reporting questionnaires 
(36, 38). The Europ-ASI and the self-reporting questionnaires were also completed at the 




Opioid-dependent individuals who expressed interest in the study were given detailed 
information about the study, in particular about the possible effects and side effects of XR-
NTX. Information was provided both verbally and in writing, and participants were given a 
copy of their written informed consents. Participants were able to withdraw from the study at 
any time, and could commence substitution medication as part of OMT on the day of study 
discontinuation if medically feasible.  
The study was approved by the Regional Committee for Medical and Health Research Ethics 
(# 2011/1320), the Ethical Boards of the participating hospitals and the Norwegian Medicines 
Agency (EudraCT:2011-002858-31).  
Statistical analyses 
In this exploratory analysis of data from a previously published 9-month follow-up study, we 
included the participants based on affiliation to the OMT program prior to study. Categorical 
characteristics were presented as frequencies and percentages. Distribution of continuous 
characteristics was assessed by visual inspection of histograms. Symmetrically distributed 
variables were described by means and standard deviations (SD). Medians and minimum 
and maximum values were presented in addition to mean and SD for skewed variables. 
Differences between the study participants regarding their affiliation to the OMT program 
prior to inclusion were assessed by χ2-test for categorical data and independent samples t-
test or quantile regression for continuous data when the variables of interest were skewed. 
Kaplan–Meier survival curves were plotted and log-rank test performed to assess the 
differences between OMT and not OMT groups in retention in treatment. All participants who 
took at least one dose of XR-NTX during the 9 months (n=117) were included in the 
analyses. 
Results with p-values below 0.05 were considered statistically significant. All tests were two-





Participant characteristics  
Participants characteristics in the 9-month follow-up study (n=117) has previously been 
published (34). Before study enrolment, n=47 (40.2%) of participants did not attend any OMT 
program. Table 1 provides a comparison of characteristics and addiction-related problems 
between participants enrolled in OMT and not enrolled in OMT before study inclusion.  
Table 1 about here> 
There were no statistically significant differences between the OMT and non-OMT groups in 
age at onset of heroin use, in duration of heroin use or in age at onset of injecting. Neither 
were there any significant differences between the groups in age at onset or in previous use 
of alcohol, cannabis or benzodiazepines.  
Participants enrolled in OMT before study inclusion reported less current addiction-related 
problems, but showed higher scores on parameters associated with long-term addiction-
related health problems such as number of non-lethal overdoses (difference between 
medians of 2.0 (95% CI: 0.2; 3.8), p=0.032), years of injecting drug use (difference between 
medians 3.0 (CI: 1.4; 7.4), p=0.180), and being Hepatitis C sero-positive (65.7% vs 31.9%, 
p=0.002). As expected, OMT participants reported a higher consumption of substitution 
medication during the last 30 days before study enrolment (difference between medians 26.0 
(CI: 17.3; 30.0), p<0.001). 
Conversely, participants not in OMT prior to study inclusion reported higher scores on 
parameters indicating more severe ongoing addiction-related problems in the last 30 days 
before study inclusion: More use of heroin (difference between medians -15.0 (CI: -24.6; -
5.4), p=0.002) and more money spent on illicit substances (difference between medians  -
6000 (CI: -10103; -1897), p=0.004) (table 1). Further, heroin was to a greater extent their 
major opioid addiction compared to those enrolled in OMT (76.1 %, respectively 53.8 %).  
Retention in treatment 
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At the start of the 9-month follow-up, 59.8% (n=70) of the participants were enrolled in OMT 
and 40.2% (n=47) were not prior to study inclusion.  
At the end of the 9-month follow-up, 50% (n=29) of the n=58 completers came from OMT 
and 50% (n=29) did not prior to study inclusion. The non-OMT group displayed significantly 
longer retention in treatment compared to the OMT group (mean weeks 28.3 (CI 25.2; 31.4) 
vs 23.7 (CI 20.9; 26.6), p=0.048 for log-rank test) (figure1).   
<Figure 1 about here> 
 
Discussion 
Offering extended-release naltrexone (XR-NTX) for the first time in Norway and in Western 
Europe attracted a representative sample of opioid-dependent individuals. The participants’ 
characteristics were within the range of variability previously documented in other studies of 
opioid-dependent individuals (19, 35, 39, 40).  
Our study showed that XR-NTX seemed to attract a proportion of opioid-dependent 
individuals who appear to have been unwilling to receive OMT. These participants (40.2%) 
reported more severe ongoing addiction-related problems compared to the participants 
recruited from the OMT-population, and were at higher risk of overdose due to their pattern 
of uncontrolled use of illicit substances (35). In a previous survey performed by our research 
group, opioid-dependent individuals not currently in OMT reported a higher interest in XR-
NTX treatment than those enrolled in OMT (32). Thus, a number of opioid-dependent 
individuals whom for different reasons have chosen not to be enrolled in an available OMT 
treatment, have shown, both in attitude and in behaviour, attraction to XR-NTX treatment. 
Furthermore, these participants maintained significantly longer in XR-NTX treatment, 
compared to those enrolled in OMT prior to study inclusion. This is an encouraging finding 
suggesting that a substantial numbers of these individuals could benefit from XR-NTX 
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treatment, and furthermore entail an increase in number of opioid-dependent individuals in 
treatment.  
Existing OMT patients comprised the majority of XR-NTX volunteers (59.8%) who by 
volunteering for medication-assisted abstinence with XR-NTX took action towards 
discontinuing their daily agonist maintenance medication (usually buprenorphine). These 
OMT participants reported a more severe history of addiction-related health problems, but in 
line with previous studies, both health and psychosocial factors improved while these 
participants were in OMT (4, 5). However, OMT enrolment do also carry a burden for 
individuals, such as daily monitored intake of opioids and frequent urine drug testing, and a 
perception of stigma and a manifestation of an addictive identity (26, 27, 41, 42). Although 
OMT being an effective treatment alternative, studies have shown that intravenous misuse of 
OMT-medication and illicit substances is not uncommon among OMT-populations (43). In 
contrast, studies of XR-NTX treatment have reported rather low rates of opioid use, reduced 
heroin craving, a high degree of treatment satisfaction and increased life satisfaction, 
suggesting XR-NTX as a potential effective treatment option (28, 29, 34). 
Previous studies have reported that many patients in OMT express a main goal of opioid 
abstinence (33, 44, 45). The before mentioned  survey conducted by our research team, also 
discovered a high interest in XR-NTX treatment among OMT-patients (32). Since 
discontinuing substitution medication is risky even when patients are highly motivated, rather 
few succeed in detoxification from OMT and many relapse to opioid use (46). This implies 
that opioid-dependent individuals are recommended to stay in OMT, maintaining their opioid 
dependence and thus, the rate of opioid-free patients remains low (9). Treatment with XR-
NTX may offer a safer medication-assisted abstinence and be perceived by the patients as a 
strong support in a transition phase towards medication-free abstinence. XR-NTX treatment 




The difference in retention between those enrolled in and those not enrolled in OMT prior to 
study inclusion, may reflect their experience – or lack of experience – with OMT. Concerning 
the participants not enrolled in OMT prior to study inclusion, we suggest that the motivation 
for staying in XR-NTX treatment corresponded with the motivation for not enrolling into OMT. 
The administration of naltrexone implies fewer of the inconveniences of daily living that 
opioid-dependent individuals experience as hindrances for enrolment in OMT (26, 27, 42). 
On the contrary, participants previous enrolled in OMT who experienced improvements in 
various addiction-related problems during this treatment may more easily return to OMT-
treatment if they disliked any effects of XR-NTX. The study personnel also experienced that 
a number of OMT participants were satisfied with a shorter period of time in treatment, and 
ended their XR-NTX treatment before the pre-scheduled time. These participants had 
received treatment for opioid dependence for a longer period, were typically already 
recovered due to a successful OMT program before study inclusion, and wanted XR-NTX in 
a shorter transition phase towards a main goal of medication-free abstinence.  
Patients with severe ongoing addiction-related problems can be “hard to reach” and have 
limited contact with specialized health services (47). OMT has been shown to be effective in 
such “hard to reach” patients in low-threshold setting with regard to harm reduction purposes 
(47). Based on our clinical experience from the present study, treatment with XR-NTX could 
also be relevant for harm reduction purposes in this group of patients. One hindrance 
however, is that XR-NTX requires a complete detoxification from opioids before the first 
injection of XR-NTX can be administered. This procedure may prevent patients to be 
inducted to XR-NTX (29). If induction to XR-NTX is successful however, these patients might 
adhere more easily to a medication that is administered once every 4 weeks instead of once 
daily (28).  Further studies are needed to investigate to which degree XR-NTX could be 
effective for harm reduction purposes in this population of patients.  
Our results should be understood as hypothesis-generating for future naturalistic studies that 
could confirm the results of the present study. Previous studies have not discriminated 
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between different lengths of treatment concerning the opioid-dependent individuals’ 
motivation for XR-NTX treatment. As for other treatment programs, XR-NTX treatment 
should be adapted according to the individual preferences and needs. This is important 
knowledge for clinicians and future studies of XR-NTX should also address this issue.  
 
Conclusions 
Opioid-dependent individuals not currently enrolled in OMT were attracted to this novel 
treatment modality and adhered longer to XR-NTX treatment than those enrolled in OMT 
prior to study inclusion. Adherence to XR-NTX treatment may be better among those who 
prefer not to enrol in OMT due to individual reasons such as less frequent dosing and/or less 
stigma of antagonist treatment. The prospects for patients in regaining opioid-abstinence with 
XR-NTX are very different from the current applied treatment in OMT, and induction to XR-
NTX may result in a paradigm shift regarding treatment of opioid-dependent individuals. We 
suggest that XR-NTX has the potential to increase the overall number of opioid-dependent 
individuals in treatment, and that XR-NTX should be an available treatment option to opioid-
dependent individuals in Europe.   
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Table 1 Differences within the study group 
 In OMT  
n=70 (59.8%) 








Gender    0.0602 
 Male 49 (70.0) 40 (85.1)   
 Female  21 (30.0) 7 (14.9)   
Age  36.2 (7.9) 34.6 (9.1)  0.3094 
Substitution medication, 
days of use last 30 days 
    
 N 68 46   
 Mean (SD)  18.0 (13.5) 7.9 (10.8)   
 Median (min-max) 28 (0-30) 2 (0-30) 26.0  
 
<0.0011 
Heroin, days of use last 
30 days 
    
 N 67 46   
 Mean (SD) 7 (10.7) 14.5 (12.4)   
 Median (min-max) 0 (0-30) 15 (0-30) -15.0  
(-24.6;-5.4) 
0.0021 
Years with injection use      
 N 66 45   
 Mean (SD) 11.0 (8.8) 8.5 (9.3)   
 Median (min-max) 8 (0-40) 5 (0-35) 3.0 (-1.4;7.4) 0.1801 
Hepatitis C sero-positive     <0.0022 
 Don’t know, N (%) 1 (1.4) 2 (4.3)   
 No, N (%) 23 (32.9) 30 (63.8)   
 Yes, N (%) 46 (65.7) 15 (31.9)   
Overdoses lifetime     
 N 68 46   
 Mean (SD) 6 (8.6) 2.6 (3.9)   
 Median (min-max) 3.0 (0-50) 1.0 (0-15) 2.0 (0.2;3.8) 0.0321 
Acquisitive crime last 30 
days 
    
 N 69 45   
 Mean (SD) 4.9 (9.9) 8.0 (11.6)   
 Median (min-max) 0 (0-30) 0 (0-30)  NA3 
Money spent on illlicit 
substances last 30 days 
(NOK) 
    
 N 69 46   
 Mean (SD) 6746 (12220) 13139 
(158909) 
  











Figure 1 Survival curve for retention in treatment 
Survival curve for retention in treatment, based on participants affiliation to OMT. The curve 
display retention in the 9-month follow-up.  
 
